Skip to main content
Clinical Trials/IRCT20180421039376N1
IRCT20180421039376N1
Completed
Phase 3

Escitalopram efficacy on quality of life and prevention of depression in breast cancer patient with mastectomy

Esfahan University of Medical Sciences0 sites75 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Esfahan University of Medical Sciences
Enrollment
75
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • Women 18\-65 y/o
  • Diagnosed with breast cancer stage I,II,IIIa and undergone modified radical mostectomy with or without chemothrapy and radiotherapy
  • Consciously agreement
  • Having at least literacy of writing and reading

Exclusion Criteria

  • Pregnancy and lactation
  • History of conductive heart diseases
  • Severe renal failure
  • Moderate to severe hepatic failure
  • History of SSRI drugs reactions and sensitivity
  • Suffering from depression mood disorders, bipolar disorders or psychotic disorders based on DSM V criteria
  • Any condition limiting life expectancy
  • Any Use of anti depression or anti anxiety drugs since 2 weeks before the study
  • Any precipitation on group or individual psychotherapy sessions since 4 weeks before the study
  • Suffering from any speech disorders

Outcomes

Primary Outcomes

Not specified

Similar Trials